


In the claims:

1. **(currently amended)** A compound corresponding to the ~~general~~ formula (I)



in which

X represents an oxygen atom or a group of formula NZ in which Z represents a hydrogen atom or a (C₁-C₆)alkyl group,

n represents a number 0, 1 or 2, and

R₁, R₂, R₃, R₄ and R₅ each represent, independently of each other, a hydrogen or halogen atom or a trifluoromethyl, trifluoromethoxy, nitro, cyano, hydroxyl, (C₁-C₆)alkyl, (C₁-C₆)alkoxy, phenoxy or phenyl group optionally substituted with a halogen atom or a trifluoromethyl, cyano, hydroxyl, (C₁-C₆)alkyl or (C₁-C₆)alkoxy group, or alternatively R₂ and R₃ together form a group of formula -OCH₂O- or -CH₂CH₂CH₂CH₂-, in the form of a base or of an addition salt with an acid.

2. **(canceled)**

3. **(previously amended)** A pharmaceutical composition comprising a compound according to Claim 1, combined with an excipient.

4. **(previously added)** A compound according to claim 1 wherein X is O, NH or NHCH₃; n is 0 or 1; R₁ is hydrogen, bromo, methyl or methoxy; R₂ is hydrogen, methyl, methoxy, trifluoromethyl, fluoro or chloro; R₃ is chloro, bromo, methyl, methoxy, nitro, fluoro, hydrogen, phenyl, trifluoromethoxy or phenoxy; or R₂ and R₃ together form a group of the formula -OCH₂O- or -CH₂CH₂CH₂CH₂-; R₄ is hydrogen; and R₅ is hydrogen or methoxy; in the form of a base or of an addition salt with an acid.

5. **(currently amended)** A method for the treatment ~~or prevention~~ of Alzheimer's disease or schizophrenia disorders linked to nicotinic receptor dysfunction which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 1.

132 6. **(currently amended)** A method for the treatment ~~or prevention~~ of Alzheimer's disease or schizophrenia disorders linked to nicotinic receptor dysfunction which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 4.
